The University of Southampton
University of Southampton Institutional Repository

Tositumomab and iodine [1311] tositumomab in the management of follicular lymphoma. An oncologist's view

Tositumomab and iodine [1311] tositumomab in the management of follicular lymphoma. An oncologist's view
Tositumomab and iodine [1311] tositumomab in the management of follicular lymphoma. An oncologist's view
Iodine [131I] tositumomab, administered in combination with unlabelled tositumomab, is a novel radioimmunotherapeutic regimen that targets the CD20 antigen present on normal and malignant B-cells. The efficacy and safety of the non-myeloablative regimen has been demonstrated in follicular and transformed follicular lymphoma over the last decade in a series of clinical studies, culminating in FDA approval in June 2003. In patients with relapsed or refractory disease some remissions have proven to be durable, and frequently longer in duration than previously administered chemotherapeutic agents. As initial therapy for advanced stage follicular lymphoma, response rates are particularly impressive. Toxicity has been principally haematological, with a single nadir at 4-6 weeks post-therapy. Administration is free of many of the side effects of conventional chemotherapy, although concerns about the long term risk of therapy related myelodysplasia persist. The challenge now comes from deciding the correct place of iodine [131I] tositumomab in treatment algorithms for follicular and other ‘indolent’ lymphomas. Sequential administration after chemotherapy is being actively investigated, as is its role in myeloablative therapy. Issues of cost-benefit aside, it is a significant development in the therapy of these ‘chronic’ malignancies.
1824-4785
305-316
Davies, A.J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Davies, A.J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af

Davies, A.J. (2004) Tositumomab and iodine [1311] tositumomab in the management of follicular lymphoma. An oncologist's view. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 48 (4), 305-316.

Record type: Article

Abstract

Iodine [131I] tositumomab, administered in combination with unlabelled tositumomab, is a novel radioimmunotherapeutic regimen that targets the CD20 antigen present on normal and malignant B-cells. The efficacy and safety of the non-myeloablative regimen has been demonstrated in follicular and transformed follicular lymphoma over the last decade in a series of clinical studies, culminating in FDA approval in June 2003. In patients with relapsed or refractory disease some remissions have proven to be durable, and frequently longer in duration than previously administered chemotherapeutic agents. As initial therapy for advanced stage follicular lymphoma, response rates are particularly impressive. Toxicity has been principally haematological, with a single nadir at 4-6 weeks post-therapy. Administration is free of many of the side effects of conventional chemotherapy, although concerns about the long term risk of therapy related myelodysplasia persist. The challenge now comes from deciding the correct place of iodine [131I] tositumomab in treatment algorithms for follicular and other ‘indolent’ lymphomas. Sequential administration after chemotherapy is being actively investigated, as is its role in myeloablative therapy. Issues of cost-benefit aside, it is a significant development in the therapy of these ‘chronic’ malignancies.

Full text not available from this repository.

More information

Published date: December 2004

Identifiers

Local EPrints ID: 73337
URI: http://eprints.soton.ac.uk/id/eprint/73337
ISSN: 1824-4785
PURE UUID: b9c66d91-a05a-41d5-a947-7039cd1da604
ORCID for A.J. Davies: ORCID iD orcid.org/0000-0002-7517-6938

Catalogue record

Date deposited: 11 Mar 2010
Last modified: 03 Feb 2020 01:30

Export record

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×